ストックスクリーナーアプリを入手
2.89
8.24%
0.22
アフターアワーズ：
2.98
0.09
+3.11%
Nrx Pharmaceuticals Inc (NRXP) 最新ニュース
NRx Pharmaceuticals Inc. Equity Warrant Bounces Off Moving Average SupportEarnings Recap Report & Daily Technical Forecast Reports - metal.it
Has NRx Pharmaceuticals Inc. formed a bullish divergenceEarnings Overview Report & Consistent Return Strategy Ideas - Newser
How to recover losses in NRx Pharmaceuticals Inc. Equity Warrant stockPortfolio Growth Summary & Capital Efficiency Focused Ideas - Newser
NRx Pharmaceuticals Inc. Equity Warrant stock outlook for YEARPortfolio Performance Summary & AI Driven Price Forecasts - Newser
NRX Pharmaceuticals WRT NRXPW 2025Q2 Earnings Preview Upside Potential Amid Strategic Developments and Market Expansion - AInvest
NRX Pharmaceuticals NRXP 2025Q2 Earnings Preview Downside Ahead on Historical Revenue and Profitability Challenges - AInvest
NRx Pharmaceuticals Inc. Equity Warrant Added to High Probability Setup ListTrade Analysis Report & AI Enhanced Trade Execution Alerts - sundaytimes.kr
NRX Pharmaceuticals Granted FDA Fast Track Designation for NRX-100. - AInvest
Real time social sentiment graph for NRx Pharmaceuticals Inc. Equity Warrant2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Can a trend reversal in NRx Pharmaceuticals Inc. lead to recovery2025 Major Catalysts & Real-Time Stock Entry Alerts - Newser
Will NRx Pharmaceuticals Inc. price bounce be sustainable2025 Valuation Update & Stepwise Entry and Exit Trade Signals - Newser
Applying chart zones and confluence areas to NRx Pharmaceuticals Inc.Trade Volume Summary & Verified Technical Trade Signals - Newser
Smart tools for monitoring NRx Pharmaceuticals Inc.’s price action2025 Market Trends & Weekly Consistent Profit Watchlists - Newser
Strategies to average down on NRx Pharmaceuticals Inc. Equity WarrantSell Signal & Free Safe Entry Trade Signal Reports - Newser
How much upside does NRx Pharmaceuticals Inc. have2025 Price Action Summary & High Accuracy Investment Signals - thegnnews.com
Published on: 2025-08-15 05:01:04 - Newser
What Technical Tools Say About NRx Pharmaceuticals Inc. Equity Warrant RecoveryGap Up & Growth Focused Entry Point Reports - beatles.ru
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - The Florida Times-Union
NRx Pharmaceuticals Delays Q2 2025 Report Filing - TipRanks
Nrx Pharmaceuticals shares rise 1.12% after-hours after rescheduling Q2 2025 financial results release. - AInvest
NRX-100 and the Fast Track to Market: How NRx Pharmaceuticals Is Revolutionizing Suicide Prevention with FDA-Backed Momentum - AInvest
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition - Yahoo Finance
NRx Pharmaceuticals to Report Q2 2025 Results on August 14 - MSN
NRx Pharmaceuticals to Report Q2 2025 Financial Results on August 14, 2025 - AInvest
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025 - BioSpace
NRx Pharmaceuticals: Navigating Regulatory Hurdles and Earnings Delays in the Race for Mental Health Breakthroughs - AInvest
NRx Pharmaceuticals Reschedules Q2 2025 Financial Results Release to August 19, 2025 - AInvest
2025-08-13 | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025 | NDAQ:NRXP | Press Release - Stockhouse
NRx Pharmaceuticals (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride From Ketamine Products - Yahoo Finance
NRx Pharmaceuticals: A Biotech Company Making Waves with Suicidal Depression Therapies and Clinics - AInvest
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street - MarketScreener
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street | FinancialContent - FinancialContent
NRx Pharmaceuticals shares fall 5.86% premarket after FDA granted Fast Track designation to NRX-100 for suicidal ideation treatment. - AInvest
Combining machine learning predictions for NRx Pharmaceuticals Inc. Equity Warrant2025 Market WrapUp & Scalable Portfolio Growth Ideas - Newser
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustai - Marco Eagle
Why NRx Pharmaceuticals Inc. stock attracts strong analyst attentionFree Investment Webinars - thegnnews.com
NRx Pharmaceuticals (NASDAQ: NRXP) CEO to Join Fireside Chat at BTIG Virtual Biotechnology Conference - Yahoo Finance
NRx Pharmaceuticals, Inc. Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression - MarketScreener
NRx Pharmaceuticals shares rise 2.59% premarket after receiving final clearance for Dura Medical acquisition. - AInvest
Is NRx Pharmaceuticals Inc. Equity Warrant stock a value trapChannel Breakout Watchlist - newsyoung.net
Why Small-Cap Biotech NRx Pharmaceuticals Is Drawing Heavy Retail Buzz - Stocktwits
FDA Grants NRX-100 Fast Track Designation for Suicidal Ideation - HCPLive
$3 Billion Suicidal Depression Market May Soon be Accessible via - openPR.com
$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025 - GlobeNewswire
NRx Pharmaceuticals stock price target raised to $21 by BTIG on FDA progress - Investing.com India
FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients With Depression, Including Bipolar Depression - Psychiatric Times
FDA grants fast track designation for NRx’s depression treatment By Investing.com - Investing.com Australia
FDA grants fast track designation for NRx’s depression treatment - Investing.com
New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation - ACCESS Newswire
Nrx Pharmaceuticals shares rise 3.17% premarket after FDA granted designation for NRX-100, expanding addressable population. - AInvest
NRx Pharma Receives FDA Fast Track Designation for NRX-100 for Treating Suicidal Ideation in Depression - AInvest
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):